mRNA Vaccine Platform

The mRNA vaccine field, which represents a promising alternative to conventional vaccine approaches, is developing extremely rapidly because of their high potency, potential for rapid development and capacity for low-cost manufacture and safe administration. With advanced technologies and years of experience in the vaccine development field, Creative Biolabs offers specialized support in the design, production, and evaluation of mRNA vaccines to bring your mRNA therapeutics for conventional protein replacement therapy closer to clinical realization.

Nucleic acid therapy has become a promising alternative to conventional vaccine methods. In 1990, in vitro transcription of mRNA successfully used in animals was reported for the first time. Reporter gene mRNAs were injected into mice and protein production was detected. Subsequent studies have found that administration of vasopressin-encoded mRNA in the hypothalamus can cause physiological responses in rats. However, these early promising results did not attract significant investment in mRNA therapeutics, primarily because of the shortcomings of mRNA, such as instability, high innate immunogenicity, and inefficient in vivo delivery. But still, once these shortcomings are overcome, the use of mRNA has many beneficial features over subunit vaccines, killed or attenuated vaccines, as well as DNA-based vaccines.

Advantages of mRNA Vaccine

• Non-infectious and non-integrating. No potential risk of infection or insertional mutagenesis.
• In vivo half-life can be regulated via various modifications and delivery methods.
• The inherent immunogenicity of the mRNA can be down-modulated to further increase the safety profile.
• Various modifications can be done to make mRNA more stable and highly translatable.
• mRNA can be formulated into carriers to achieve efficient in vivo delivery.
• Capacity for low-cost and rapid scalable manufacture.

mRNA is the intermediate step between the translation of protein-encoding DNA and the production of proteins by ribosomes in the cytoplasm. Two major types of RNA have been studied as vaccines:

• Non-replicating mRNA Vaccine. Encoding the antigen of interest and contains 5′ and 3′ untranslated regions (UTRs)
• Self-amplifying RNA Vaccine. Encoding not only antigen of interest but also viral replication machinery that enables intracellular RNA amplification and abundant protein expression.

mRNA Pharmacology Optimization Platform

• Optimization of mRNA translation and stability
• Modulation of immunogenicity
• mRNA vaccine delivery

Dendritic Cell mRNA Vaccines

An effective strategy for programming DCs is to use mRNA, and the vaccine consisting of mRNA-modified DCs has shown promising results in clinical trials. Equipped with a team of professional scientists, Creative Biolabs is capable of providing specialized support in the design, production, and evaluation of mRNA-based dendritic cell vaccines.

Personalized Neoepitope mRNA Cancer Vaccines

In vitro transcription (IVT) mRNA is used for therapeutic cancer vaccination, with the advantages of self-adjuvanting activity, direct translation into cytoplasm, low risk of insertional mutagenesis, and simple and inexpensive manufacturing procedure. Creative Biolabs now provides personalized neoepitope mRNA cancer vaccine development services.

mRNA GMP Synthesis

Creative Biolabs is very proud to offer GMP-grade mRNA manufacturing for your vaccine needs. We focus not only on quality and speed but also on scalability and cost, thus we ensure that your vaccine development is supported in the most effective way. Customers can provide well-designed mRNAs or our scientists can guide you to the best design for your specific application.

For more detailed information, please feel free to contact us or directly send us an online inquiry.

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.